C4 CRE Member Presentations at the 2018 International Papillomavirus Conference 

Professor Karen Canfell

Chair: Opening Ceremony: Introduction and Welcome to Country

Public Health Workshop 5: Cervical Screening in High Income Countries

Dedicated Symposium 3: Preventing Cervical Cancer (PCC) Session 02 – Cervical Screening In Australia

IPVC Closing Plenary, Farewell and Hand-Over

Invited Speaker

1. Welcome and Introduction to the Meeting: On the Threshold of Major Action towards Global Cervical Cancer Elimination

2. Cervical Cancer Prevention in Australia

Associate Professor Julia Brotherton

Workshop Chair:

Public Health Workshop 1: Moving Forward With HPV Vaccination in High Income Countries

Public Health Workshop 3: We Can Prevent Cervical Cancer: An Australian Perspective on Closing the Gap in Aboriginal and Torres Strait Islander Health

Public Health Workshop 6: Lifting our Game: Communication and Engagement Strategies About HPV Vaccination to Overcome the Organised Anti-Vaccination Movement

Chair: IPVC 2018 Plenary Session 4

Invited Speaker:

  1. Self-Sampling With Point of Care HPV Testing in Malaysia: Project Rose
  2. One Dose of Human Papillomavirus Vaccine is as Effective as Three For Prevention of High-Grade Cervical Lesions: National Cohort Study
  3. Update on HPV Vaccine in Australia
  4. Performance of the New HPV Screening Program In Australia – The First Year

Professor Marion Saville

Public Health Workshop 5: Cervical Screening in High Income Countries

Invited Speaker:

1. COMPASS Trial Update

Professor Phil Castle

The Evidence on HPV Negative Cancers: Any Impact on the Decision to Co-Test?

Professor Suzanne Garland

Aboriginal and Torres Strait Islanders – Access, Acceptability, Disease Presentations

Professor Rebecca Guy

HPV Vaccination for Aboriginal Adolescents and Their Communities: What Do We Know About Coverage And Acceptability?

Professor Andrew Vallely

1. Rapid HPV Testing in the Field, Papa New Guinea Experience

2. Point Of Care HPV Testing as a Screen and Treat Program: The Papua New Guinea Experience

Dr Kate Simms

1. Timeline to Global Elimination of Cervical Cancer: Projections of the Impact of HPV Vaccination and Cervical Screening in 181 Countries; 2020-2099

2. Modelled Evaluation of the Population-Level Effectiveness of HPV-Faster In Low-Resource Settings and the Cost-Effectiveness Screen-And-Vaccinate Strategies in High-Resource Settings

3. How Could Therapeutic HPV Vaccines Be Used In Clinical Practice? Predicted Impact of Therapeutic Vaccination in a Clinical Setting.

Dr Allyssa Cornall

Assessment of Attribution Algorithms for Resolving Cin3-Related HPV Genotype Prevalence in Mixed-Genotype Biopsy Specimens Using Laser Capture Microdissection as the Reference Standard.

Clinical Associate Professor Deborah Bateson

1. FAQS in Clinical Practice

Dr Dorothy Machalek

1. Prevalence of Genital Quadrivalent Vaccine and Non-Vaccine HPV Types among Australian Women Aged 18–24 Years, a Decade after Program Implementation

2. HPV Vaccine Surveillance in Australia: Critical Data for Evaluation and Policy

3. Prevalence of Genital Quadrivalent Vaccine and Non-Vaccine HPV Types Among Australian Women Aged 18–24 Years, a Decade after Program Implementation

Dr Megan Smith

1. Participation and Outcomes from Australia’s New Program: Progress Report

2. Could Self-Collection Be An Equitable Option for Aboriginal Women? Modelling its Impact Compared to Clinician Collected Testing in the Australian Setting

3. Lives Lost Due to Vaccine Hesitancy in Japan: A Missed Opportunity and the Potential Gain If Coverage is Restored